Head-to-head · WeighScore
Trimi vs Ro
The verdict
Trimi takes it — 86/100 to 78/100.
Trimi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Bottom-quartile pricing on both molecules under one flat membership, shipped free nationwide — a strong-value pick sitting just behind the top tier.
Assume any provider we list may compensate us — we may earn a commission at no cost to you. It never changes the WeighScore.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Trimi | Ro |
|---|---|---|
| WeighScore | 86/100 | 78/100 |
| Grade | B | C+ |
| Scorecard rank | #6 | #30 |
| Semaglutide | $129/mo | Not disclosed |
| Tirzepatide | $199/mo | Not disclosed |
| Coverage | All 50 states | Multi-state |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Yes |
Graded #6 · B
Strengths
- Low flat pricing on both semaglutide and tirzepatide
- Both molecules on a single membership
- Free shipping to all 50 states
- Fast dispatch once the prescriber signs off
Where it loses points
- Compounded only — no brand-name Ozempic/Wegovy or Mounjaro/Zepbound
- Injection only — no oral or sublingual route
- Dispensing pharmacy not publicly named
- Shorter public track record than the incumbents
Graded #30 · C+
Strengths
- Brand-name access + insurance support
- Oral options
- Well-funded platform
Where it loses points
- Does not disclose compounded pricing up front
- Premium positioning
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 31 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.